APA (7th ed.) Citation

Alten, R., Östör, A., Edwards, C. J., Smolen, J. S., Haladyj, E., Ng, K. J., . . . Kaneko, Y. (2026). Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study. Rheumatology & Therapy, 13(1), 231. https://doi.org/10.1007/s40744-025-00815-0

Chicago Style (17th ed.) Citation

Alten, Rieke, Andrew Östör, Christopher J. Edwards, Josef S. Smolen, Ewa Haladyj, Khai Jing Ng, Samuel Ogwu, and Yuko Kaneko. "Long-Term Effectiveness of Baricitinib and Other B/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study." Rheumatology & Therapy 13, no. 1 (2026): 231. https://doi.org/10.1007/s40744-025-00815-0.

MLA (9th ed.) Citation

Alten, Rieke, et al. "Long-Term Effectiveness of Baricitinib and Other B/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study." Rheumatology & Therapy, vol. 13, no. 1, 2026, p. 231, https://doi.org/10.1007/s40744-025-00815-0.